tradingkey.logo
tradingkey.logo
Search

Eli Lilly and Co

LLY
Add to Watchlist
1186.360USD
-5.580-0.47%
Close 08-06 16:00ETQuotes delayed by 15 min
1.12TMarket Cap
42.07P/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-0.47%

5 Days

+2.72%

1 Month

-1.14%

6 Months

+12.11%

Year to Date

+10.39%

1 Year

+58.95%

Key Figures
1191.330Open
1194.535High
2.57MVolume
42.07P/E TTM
27.19P/E Dynamic
6.230Dividend TTM
0.27%Turnover Ratio
1191.940Prev. Close
1161.200Low
1.73BTurnover
105.70P/E Static
35.88P/B
0.53%Div Yield TTM
24.54%ROA
1149.10052wk High
0.65Volume Ratio
10.59BNet Profit
943.50MShares
28.2003EPS TTM
0.53Beta
107.65%ROE
623.78052wk Low
2.80%Amplitude
85.78%Gross Margin
1.12TMarket Cap
0.16Reward/Risk
1.78%Risk Rate

Recent

Analysis

Earnings

Novo Nordisk A/S Stock (NVO) Closed Up by 3.11% on Aug 6: What Investors Need To Know

• Novo Nordisk raised full-year sales and operating profit guidance amid strong metabolic drug demand. • Clinical data shows efficacy for cardiovascular and kidney diseases, expanding the potential patient base. • Current technical indicators show a neutral MACD signal and oversold Williams %R conditions.

TradingKeyThu, Aug 6

Insmed Inc Stock (INSM) Moved Up by 31.83% on Aug 6: Key Drivers Unveiled

• Insmed shares rose following positive clinical trial data and potential acquisition interest. • Analysts revised revenue models, setting an average price target of $196.74. • Technical indicators show a sell signal with the stock currently in oversold territory.

TradingKeyThu, Aug 6

Mckesson Corp Stock (MCK) Moved Down by 3.44% on Aug 6: What Signal Does It Send?

• McKesson shares declined following margin contraction in the U.S. Pharmaceutical segment. • Management maintained full-year earnings guidance, disappointing investors seeking an upward revision. • Regulatory scrutiny regarding drug pricing and reimbursement creates significant uncertainty for the firm.

TradingKeyThu, Aug 6

Mckesson Corp Stock (MCK) Closed Up by 5.08% on Aug 5: What Investors Need To Know

• McKesson reported fiscal first-quarter earnings exceeding consensus expectations across core metrics. • Management raised full-year earnings guidance, citing strength in oncology and biopharma services. • The company leads its industry with $403.43 billion in latest annual revenue.

TradingKeyWed, Aug 5

Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.10% on Aug 5: Key Drivers Unveiled

• Bristol-Myers Squibb lowered its financial outlook due to high costs replacing aging drugs. • Investors are concerned about slow adoption rates for the company's new product launches. • Federal drug pricing negotiations create valuation uncertainty and a price ceiling for shares.

TradingKeyWed, Aug 5

Amgen Inc Stock (AMGN) Moved Up by 4.57% on Aug 5: Drivers Behind the Movement

• Amgen shares rose following strong quarterly earnings and increased full-year guidance. • Positive clinical trial updates for the obesity drug MariTide boosted investor confidence. • Analysts raised price targets citing improved margins and robust product portfolio growth.

TradingKeyWed, Aug 5

Eli Lilly and Co's Score

0.01vs previous score
Forecast8.12
Financial Health8.41
Technical3.08
Valuation Dimensions8.74
Institutional Confidence10.00
Risk Assessment8.80

Media Coverage

Coverage Level

49°C

Very Low
Very High
Neutral

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
1245.374Target Price
+11.62%Upside Space
Current Rating2026-082026-072026-062026-052026-042026-032026-022026-01
Strong Buy101010111110109
Buy1717171616141515
Hold66778989
Sell11110000
Strong Sell00000000

Eli Lilly and Co Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D

Technical Indicators

Buy

Summary

Buy

Moving Average

Strong buy

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
2026-08-05
Reporting Period
2026Q2
Earnings / Forecast
7.95/6.01
Revenue / Forecast
22.97B/20.73B

Eli Lilly and Co Profile

SectorPharmaceuticals
Ticker SymbolLLY
Number of employees47000
CountryUnited States of America

Ownership

ShareholdersProportion
Lilly Endowment, Inc.9.76%
Vanguard Capital Management, LLC5.67%
PNC Investments LLC5.43%
BlackRock Institutional Trust Company, N.A.4.44%
Shareholder TypesProportion
Investment Advisor46.65%
Investment Advisor/Hedge Fund19.18%
Foundation9.76%
Research Firm2.14%

FAQs

What is the current price of Eli Lilly and Co (LLY)?

The current price of Eli Lilly and Co (LLY) is 1190.66.

What is the symbol of Eli Lilly and Co?

The ticker symbol of Eli Lilly and Co is LLY.

What is the 52-week high of Eli Lilly and Co?

The 52-week high of Eli Lilly and Co is 1149.10.

What is the 52-week low of Eli Lilly and Co?

The 52-week low of Eli Lilly and Co is 623.78.

What is the market capitalization of Eli Lilly and Co?

The market capitalization of Eli Lilly and Co is 1.12T.

Is Eli Lilly and Co (LLY) currently rated as Buy, Hold, or Sell?

According to analysts, Eli Lilly and Co (LLY) has an overall rating of Buy, with a price target of 1245.37.

What is the Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY)?

The Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY) is 23.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.